l e t t e r S
Excess levels of protein in urine (proteinuria) is a hallmark of kidney disease that typically occurs in conjunction with diabetes, hypertension, gene mutations, toxins or infections but may also be of unknown cause (idiopathic) 1 . Systemic soluble urokinase plasminogen activator receptor (suPAR) is a circulating factor implicated in the onset and progression of chronic kidney disease (CKD) 2 , such as focal segmental glomerulosclerosis (FSGS) 3, 4 . The cellular source(s) of elevated suPAR associated with future and progressing kidney disease is unclear, but is likely extra-renal, as the pathological uPAR is circulating and FSGS can recur even after a damaged kidney is replaced with a healthy donor organ. Here we report that bone marrow (BM) Gr-1 lo immature myeloid cells are responsible for the elevated, pathological levels of suPAR, as evidenced by BM chimera and BM ablation and cell transfer studies. A marked increase of Gr-1 lo myeloid cells was commonly found in the BM of proteinuric animals having high suPAR, and these cells efficiently transmit proteinuria when transferred to healthy mice. In accordance with the results seen in suPARassociated proteinuric animal models, in which kidney damage is caused not by local podocyte-selective injury but more likely by systemic insults, a humanized xenograft model of FSGS resulted in an expansion of Gr-1 lo cells in the BM, leading to high plasma suPAR and proteinuric kidney disease. Together, these results identify suPAR as a functional connection between the BM and the kidney, and they implicate BM immature myeloid cells as a key contributor to glomerular dysfunction.
FSGS is a common primary glomerular disease leading to kidney failure, necessitating dialysis or kidney transplantation 5 . It is characterized morphologically by segmental sclerosis in some glomeruli; clinically, it is characterized by proteinuria 6, 7 . About 80% of FSGS cases are primary or idiopathic. FSGS recurs in newly transplanted kidneys in 30% of adults and even more frequently in children 8 . Because of the rapid onset of FSGS recurrence after transplantation, circulating factors have been considered as pathogenic causes [9] [10] [11] [12] . We previously reported that suPAR is one such circulating factor in FSGS, and we demonstrated that suPAR binds to and activates β3 integrin on the podocyte membrane. This leads to podocyte foot process effacement and disrupted glomerular barrier function, resulting in proteinuria 3, 4 . Furthermore, as relatively high levels of suPAR associate with lower kidney function, prospective cohort studies in humans were subsequently performed: through these, suPAR has recently emerged as a risk factor for the incidence and progression of CKD 2 .
Circulating suPAR can be generated by release from the membranebound form of urokinase plasminogen activator receptor (uPAR), a glycosylphosphatidylinositol (GPI)-anchored three-domain (DI, DII and DIII) signaling protein 13, 14 . suPAR exists in multiple forms due to alternative splicing, protein glycosylation and enzymatic cleavage of the mature protein 15 . While mounting experimental and clinical evidence suggests that suPAR is involved in the pathogenesis of CKD, the cellular source(s) of elevated suPAR remains unknown. Thus, identifying the cellular source(s) of suPAR that are relevant to kidney disease is one essential step required for the exploration of potential therapeutics aimed at the treatment of suPAR-related renal dysfunction such as that seen in FSGS.
Experimental studies have shown that mice injected with lipopolysaccharides (LPS) as a model of glomerular injury display a transient proteinuria associated with podocyte foot process effacement 3, 4, 16, 17 , as well as some renal lesions similar to FSGS in humans 18 . Based on our previous findings that uPAR deficiency protects against Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease LPS-induced proteinuria and podocyte injury 3,4 , we first tested the contribution of hematopoietic cells on suPAR production and proteinuria development in the LPS model using a bone marrow transplantation (BMT) technique (Fig. 1a) . We have successfully generated BM chimeric mice in which the recipient uPAR-deficient knockout (Plaur −/− , KO) mice were irradiated and reconstituted with BM cells of either uPAR wild-type (Plaur +/+ , WT) or uPAR KO mice ( Supplementary Fig. 1 , WT→KO; 94.6% ± 3.7, KO→KO; 99.3% ± 0.7). As expected, KO→KO chimeric mice showed a strong defect in suPAR production (Fig. 1b,c) with a lack of proteinuria development (Fig. 1d) upon LPS stimulation. In contrast, the chimeric mice expressing uPAR selectively within hematopoietic cells (WT→KO) exhibited elevated suPAR levels in both blood and urine (Fig. 1b,c) , as well as proteinuria (Fig. 1d) , following LPS stimulation. These results suggest that hematopoietic cells are sufficient for the production of suPAR and the development of proteinuria in this model.
We further tested if the ablation of BM cells via irradiation could prevent suPAR-associated proteinuria following LPS treatment (Fig. 1e) . Irradiation before LPS injection led to a marked reduction in the degree of proteinuria ( Fig. 1f and Supplementary Fig. 2a,b) as well as in plasma suPAR levels (Fig. 1g) in BALB/c mice. However, when irradiated mice were reconstituted with unstimulated BM cells, they once again displayed proteinuria (Fig. 1f) with elevated plasma suPAR levels (Fig. 1g) upon LPS treatment.
Given that hematopoietic cells are categorized into lymphoid cells and myeloid (erythro-myeloid) cells, we next examined which cell lineages participate in suPAR-associated proteinuria. This was accomplished by taking advantage of NOD-scid IL-2rγ null (NSG) mice, in which the white blood cell population is comprised of predominantly myeloid-lineage cells due to the lack of mature lymphocytes: T cells, B cells and natural killer (NK) cells 19 . Despite impaired lymphoid populations, these NSG mice showed comparable levels of suPAR and proteinuria to BALB/c WT mice upon LPS administration ( Fig. 1h-j) . Based on these observations and previous findings 16, 17 , we could rule out the contribution of mature lymphocytes on suPAR-associated proteinuria in this model and focus on cells of the myeloid lineage.
To define the nature of the myeloid cells in the LPS proteinuric mice, we studied the expressions of uPAR and of the mouse myeloid differentiation antigen Gr-1 in BM cells as well as in peripheral blood leukocytes. In LPS-treated animals, BM Gr-1 + myeloid cells-but not peripheral blood Gr-1 + cells-exhibited elevated levels of uPAR on their membrane when compared to phosphate-buffered saline (PBS)-treated mice (Fig. 2a) . The surface expression of Gr-1 is representative of the maturation status of myeloid cells 20 . In the BM, the level of Gr-1 expression is low on myeloid progenitors or immature cells and increases as they mature to granulocytes. Of note, LPS stimulation led to a marked increase in the percentage of Gr-1 lo cells in the BM of WT mice ( Fig. 2b and Supplementary Fig. 3a,b) . However, loss of granulocyte colony-stimulating factor (G-CSF) receptor (G-CSFR), a major regulator of myelopoiesis 21 , resulted in impaired expansion of Gr-1 lo BM myeloid cells upon LPS treatment (Fig. 2b) and, accordingly, in lower levels of proteinuria (Fig. 2c) . We therefore hypothesized that the reactive expansion of immature myeloid cell populations in BM may contribute to the pathogenic kidney process. To test this, we used two conditions-antibody-induced peripheral neutropenia and G-CSF treatment-as myeloid cell production can be stimulated either through feedback regulation in response to peripheral neutropenia or via direct supplementation with G-CSF. Injection of Ly6G-specific monoclonal antibody resulted in depletion of peripheral mature neutrophils (Supplementary Fig. 4a,b) and augmented the degree of proteinuria in LPS-challenged mice (Supplementary Fig. 4c) . Similarly, G-CSF stimulated myelopoiesis (Supplementary Fig. 4d,e) , accelerated proteinuria and elevated plasma suPAR levels as compared to LPS treatment alone ( Supplementary Fig. 4f,g ). Together, these data suggest that increased myelopoiesis amplifies suPAR-associated proteinuria in the LPS model.
Given the recent discovery of suPAR as a risk factor for CKD 2 , we reasoned that the expansion of Gr-1 lo immature myeloid cells in the BM could be a common feature of suPAR-associated proteinuric kidney disease. We subsequently examined the levels of suPAR and Gr-1 lo BM myeloid cells in additional animal models of proteinuria that included (i) TGF β 1 Tg (transforming growth factor beta 1 transgenic), a mouse model that develops severe fibrosing kidney disease 22, 23 ) and KO→KO (n = 5) mice that were injected with LPS. Urinary albuminto-creatinine ratio (ACR) was calculated and used as a parameter to determine proteinuria. Data are shown as mean ± s.e.m.; unpaired twotailed Student t-test, *P < 0.05, ***P < 0.001. (e) Schematic diagram outlining the experimental design for irradiation and BM reconstitution studies. (f,g) Proteinuria (f) and plasma suPAR levels (g) in BALB/c WT mice that were irradiated (+) or not (−), followed by injection of freshly isolated BMCs (+) or PBS (−), before LPS stimulation. The results are from two independent experiments (n = 8 for PBS, n = 5 for LPS and Irradiation + BMC + LPS, n = 6 for Irradiation + LPS). Data are shown as mean ± s.e.m. One-way ANOVA, followed up by Tukey′s multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001. (h-j) Examination of serum (h) and urinary (i) suPAR levels and proteinuria (j) in NSG mice injected with either PBS or LPS (n = 4 per group from two independent experiments). Data are shown as mean ± s.e.m.; unpaired two-tailed Student t-test, *P < 0.05. l e t t e r S of glomerulonephritis (GN) 24 , and (iii) BTBR ob/ob mice, a mouse model of diabetic nephropathy (DN) 25 . All tested animals exhibited proteinuria after their respective induction (Fig. 2d) . Elevated suPAR levels were detected in the urine of TGF β 1 Tg mice that typically have severe, nonselective proteinuria and in both blood and urine samples of NTS and DN models. These elevated suPAR levels were accompanied by an expansion in Gr-1 lo BM myeloid cells (Fig. 2d) as seen in the LPS model.
Further testing with additional models of proteinuria shows a potential difference in the disease process between suPAR-mediated . Their relevant controls were used as described in the Online Methods. Data are shown as mean ± s.e.m.; unpaired two-tailed Student t-test, *P < 0.05, **P < 0.01, ***P < 0.001, NS, not significant. (e-h) Examination of proteinuria (e), suPAR levels in the serum (f) and urine (g) and the percentages of Gr-1 lo cells in BM (h) of LPS injected and Pod-Rac1 transgenic mice. Their relevant controls were used as described in the Online Methods. In e n = 10 for PBS, n = 16 for LPS, n = 5 for control+DOX, n = 7 for Pod-Rac1+DOX); in f n = 6 for PBS, n = 11 for LPS, n = 4 for control+DOX, n = 5 for Pod-Rac1+DOX; in g n = 8 for PBS, n = 8 for LPS, n = 4 for control+DOX, n = 5 for Pod-Rac1+DOX; in h n = 5 per group. Data are shown as mean ± s.e.m.; unpaired two-tailed Student t-test, **P < 0.01, ***P < 0.001, NS, not significant. (i,j) Proteinuria (i) and urinary suPAR levels (j) in the NTS-injected C57BL/6 mice receiving PBS (NTS + vehicle, n = 3) or BMT (NTS + BMT, n = 3). Data are shown as mean ± s.e.m.; unpaired two-tailed Student t-test, *P < 0.05. and suPAR-independent forms of disease. We tested blood and urine suPAR levels along with Gr-1 lo cell populations in a genetic and a pharmacological model of podocyte injury. NEF-rtTA:Rac1 is a double transgenic mouse line where the expression of active Rac1 is induced in a podocyte-specific manner when animals are fed a diet that includes doxycycline (DOX) (hereafter referred as Pod-Rac1) 26 . Adriamycin (ADR) can induce nephropathy by causing toxin-mediated podocyte mitochondrial damage 27 . Unlike the suPAR-associated proteinuric models previously mentioned, the Pod-Rac1 (Fig. 2e) and ADR ( Supplementary Fig. 5a ) models, in which podocytes are the direct target of injury, did not exhibit elevated suPAR levels in the blood or urine (Fig. 2f,g and Supplementary Fig. 5b,c) . Furthermore, there was no significant increase of the percentage of Gr-1 lo myeloid cells in the BM (Fig. 2h and Supplementary Fig. 5d ). Taken together, these results suggest that expansion of Gr-1 lo BM myeloid cells could be a common upstream event that leads to systemic suPAR elevation, resulting in podocyte injury and proteinuria development in certain forms of kidney disease. Next, we set out to test the therapeutic effect of BMT in suPARassociated kidney dysfunction. NTS administration induced proteinuria and increased suPAR levels, reaching a peak at day 3 (Fig. 2i,j) . However, the proteinuria following NTS injections was substantially ameliorated by irradiation and reconstitution with normal BM cells on day 2, and urinary suPAR levels were also reduced (Fig. 2i,j) . BMT also ameliorated NTS-induced renal damage, including crescent formation and glomerular sclerosis ( Supplementary  Fig. 6a,b) . These results support the notion that BM plays an important role in suPAR-associated glomerular dysfunction, acting as an upstream regulatory system.
Our group 4 and others 28 (GenBank accession NM_011113, without GPI anchor) have previously reported that injection either of fulllength suPAR into uPAR KO mice or of a shorter form of suPAR (GenBank accession BC010309) into WT mice leads to rapid proteinuria. Subsequent studies 29, 30 have shown that full-length suPAR injected into WT mice does not elicit a rapid proteinuric response unless combined with some other podocyte-injurious molecule such as anti-CD40 autoantibody 31 . Given the recent insight that elevated suPAR predicts CKD several years before its onset, we tested the effect of chronic exposure of suPAR on podocyte injury by generating a novel transgenic mouse model (suPAR-Tg) that expresses mouse suPAR (full length: DIDIIDIII, without GPI anchor) under the control of the adipocyte protein 2 (aP2, also known as Fabp4) promoter. This model, in contrast to shorter timed suPAR exposure models 29, 30 , allows for the analysis of long-term effects of high levels of suPAR (Supplementary l e t t e r S Fig. 7a) , as large amounts of suPAR can be generated from adipocytes of the transgenic mice fed a high-fat diet with a consequent release into the circulation (Supplementary Fig. 7a ). At 16 weeks of age (and after being on a high-fat diet for the prior 8 weeks), suPAR-Tg mice exhibited a marked increase of suPAR expression in adipose tissues along with elevated plasma suPAR levels as compared to littermate controls ( Supplementary Fig. 7b,c) . Subsequently, these mice developed relatively mild but significant albuminuria (Supplementary Fig. 7d , P = 0.016) with podocyte foot process effacement ( Supplementary  Fig. 7e ), implying a disruption in kidney filter function. Evidence continues to accumulate pointing to suPAR as being causative and not merely a biomarker for kidney disease 4, 28, 31, 32 . Thus, we hypothesized that Gr-1 lo BM myeloid cells harvested from proteinuric mice may be able to induce proteinuria when injected into healthy animals (Fig. 3a) . To test this, BM cells isolated from PBS-or LPS-injected NSG mice were adoptively transferred into unchallenged NSG recipient mice. Indeed, transfer of LPS-challenged BM cells induced proteinuria in healthy recipient mice (Fig. 3a) . Similarly, LPS-challenged WT C57BL/6 mouse BM cells were able to stimulate proteinuria ( Fig. 3b and Supplementary Fig. 8a,b) and increase suPAR levels ( Supplementary Fig. 8c,d ) in recipient mice, whereas these effects were abrogated when Plaur −/− BM cells were transferred (Supplementary Fig. 8) . However, the BM cells of PodRac1 proteinuric mice did not cause proteinuria (Fig. 3b) , suggesting that podocyte injury per se does not induce Gr-1 lo BM myeloid cells to become kidney pathogenic; this interpretation is consistent with low systemic suPAR levels and low percentage of Gr-1 lo myeloid cells in BM of Pod-Rac1 proteinuric mice.
Since Gr-1 lo myeloid cells in the BM are heterogeneous, we sought to determine which subsets of uPAR-expressing Gr-1 lo cells are responsible for the development of proteinuria. Given that stem cell antigen-1 (Sca-1) is expressed on mouse hematopoietic stem/progenitor cells (HSPCs) 33 and the expression is markedly enhanced by particularly primitive myeloid and granulopoietic progenitors during bacterial infection 34 , we examined Sca-1 expression in uPAR-expressing Gr-1 lo BM cells. LPS stimulation increased a uPAR-expressing BM cell population (shown in blue in Fig. 3c ) that is Sca-1 lo Gr-1 lo , suggesting that uPAR-expressing cells are myeloid-lineage-committed cells (defining immature myeloid cells) (Fig. 3c,d) . To test whether the immature myeloid cells are capable of secreting suPAR, we studied suPAR secretion using in vitro BM cell culture under LPS stimulation (Fig. 3e) . Consistent with the results from our in vivo studies, LPS stimulated the expansion of uPAR-expressing immature myeloid cells (Fig. 3f) as well as suPAR secretion (Fig. 3g) into the culture medium (CM) in a dose-dependent manner. To further evaluate if these cells can transfer disease when injected into healthy mice, Sca-1 + cells were depleted from LPS-challenged BM cells by magnetic separation before transfer into NSG mice ( Fig. 3h and Supplementary Fig. 9 ). The removal of Sca-1 + BM cells lowered both proteinuria (Fig. 3i) and suPAR levels (Fig. 3j,k) when compared with that in non-depleted control BM cells. These results emphasize the primary role of BM immature myeloid cells in the regulation of suPAR production and proteinuria development.
In an effort to translate our findings to human disease, we used a humanized mouse approach [35] [36] [37] . A model commonly used is the immunodeficient mouse engrafted with human hematopoietic cells, such as peripheral blood mononuclear cells (PBMCs) or hematopoietic stem/progenitor cells (HSPCs). A previous report 38 demonstrated that transfer of CD34 + HSPCs from individuals with glomerular diseases into healthy mice can induce albuminuria, but offered no mechanism. Thus, we hypothesized that human CD34 + cells isolated from individuals with recurrent FSGS might induce proteinuria via suPAR-driven podocyte injury. To test this hypothesis, we introduced whole PBMCs or PBMCs depleted of CD34 + cells (CD34∆ PBMCs) derived either from individuals with recurrent FSGS or from healthy individuals into the NSG mice (Fig. 4a) . Engraftment rate of human cells was determined by the percentage of human CD45 + cells in the blood and BM of the recipient xenograft animals (Supplementary Fig. 10a ). Mice receiving patient whole PBMCs, but not CD34∆ PBMCs, developed proteinuria (Fig. 4b) in association with high mouse suPAR levels in both blood and urine (Fig. 4c,d ). These mice also had a higher percentage of Gr-1 lo population in BM (Fig. 4e) , similar to what we observed in the suPAR-associated proteinuric animal models. This disease phenotype was prevented by depleting CD34 + cells from the samples of individuals with FSGS ( Fig. 4b-e) . Proteinuria in mice receiving patient whole PBMCs was accompanied by mild glomerular sclerosis (Supplementary Fig. 10b ) and podocyte foot process effacement (Fig. 4f) . These mice also exhibited elevated blood urea nitrogen (BUN) levels, increased kidney weight and enlarged, loosely structured glomeruli ( Supplementary Fig. 10c -e) reminiscent of human FSGS. It is unlikely that the observed impairment in kidney function was due to graft-versus-host disease (GVHD) since PBMCs from the healthy individuals, as well as those depleted of CD34 + cells derived from individuals with recurrent FSGS, did not cause kidney injury.
In contrast, using a mouse model of GVHD, we observed both weight loss and a mortality rate of 80% within 3 weeks in the mice receiving allogeneic BM cells (Supplementary Fig. 11a,b) . The xenograft mice did not exhibit body weight loss (Supplementary Fig. 12a ). Moreover, only negligible glomerular deposits of human IgGs were observed ( Supplementary Fig. 12b ), as well as very mild lymphocyte infiltration in the skin and liver of the xenograft mice ( Supplementary  Fig. 12c ). Since GVHD is mainly caused by donor T cells, we repeated the xenograft experiment with PBMCs depleted of T cells to avoid the risk of GVHD in the xenograft model. Consistently, we found that T-cell-depleted PBMCs from individuals with recurrent FSGS were sufficient to induce proteinuria and increase suPAR levels in mice ( Fig. 4g-i) . Taken together, these data suggest that engraftment of CD34 + cells derived from individuals with recurrent FSGS into NSG mice caused expansion of Gr-1 lo BM myeloid cells, leading to suPARassociated podocyte injury that results in proteinuria.
Here we demonstrate that BM myeloid lineage cells that are Gr-1 lo and Sca-1 lo are a common source for the overproduction of suPAR that fuels the development of proteinuric kidney disease. The systemic models (LPS, TGF β 1 -Tg, NTS and DN) and the xenograft mouse model of human FSGS converge at the expansion of uPAR-expressing immature myeloid cells in BM and high suPAR levels, unlike podocyte selective injury models (Pod-Rac1 and ADR) (Fig. 4j) . Given that bacterial infection induces massive myeloid cell production in BM, it seems that the LPS model is a preferentially immune-related model as compared to other models tested. Indeed, the LPS model showed the highest percentage of Gr-1 lo BM myeloid cells among the suPAR-associated proteinuric animal models. The pathogenesis of these other models may be undoubtedly more complex and heterogeneous, resulting in differing disease states and/or severity. In addition, transfer of these pathogenic myeloid cells was sufficient to cause proteinuria in healthy mice. Consistently, BMT substantially reduced suPAR levels and subsequently improved kidney function in proteinuric mice. In this study, we expand the role of BM from being merely a place for hematopoietic cell production to also being a key regulator of kidney function by expanding suPAR-generating cells. The expansion of suPAR-expressing immature myeloid cells could be a common upstream event that leads to suPAR-associated kidney injury seen in FSGS and possibly relevant to other proteinuric kidney diseases. Given the observation of increased Gr-1 lo BM cells in animal models of primary and secondary forms of glomerular disease, this finding may represent a dogma change, and this discovery may also shift the focus away from the kidney to common upstream regulatory systems with broad relevance to general forms of CKD. In accordance with the notion of a very upstream mediator of kidney disease, suPAR levels predicted incidence of CKD in people many years ahead of the onset of symptoms or the diagnosis of disease 2 .
Although we have identified uPAR-expressing BM immature myeloid cells (Sca-1 lo Gr-1 lo ) as cellular sources of suPAR responsible for damaging kidney podocytes in mice, the equivalent type of cell subset in humans remains to be determined and is not immediately identifiable given the lack of human homologs for Gr-1 or Sca-1. Thus, the identification of cellular sources of suPAR in patients followed by a relevant therapeutic regimen for proper modification could be the basis for a novel treatment of proteinuric kidney diseases that are characterized by high suPAR levels.
We engineered a xenograft mouse model of FSGS and further revealed that CD34 + HSPCs derived from individuals with recurrent FSGS are critical for development of a suPAR-associated glomerulopathy in mice. This was surprising given the rarity of CD34 + cells among PBMCs: a frequency of only 0.05-0.2%. However, the mechanism by which CD34 + cells from individuals with FSGS expand the murine myeloid cells remains elusive. According to our observations, it seems that CD34 + cells from people with suPAR-associated kidney disease are functionally different from those from healthy individuals, and these HSPCs carry and transfer information on disease pathogenesis. Similarly, Gr-1 lo BM myeloid cells generated in the systemic inflammatory models such as the LPS model increased suPAR levels and caused proteinuria, whereas Gr-1 lo BM myeloid cells produced by normal myelopoiesis did not. Supporting our hypothesis, it has been shown that HSPCs are significantly expanded and functionally altered in lupus model mice, with skewing toward myeloid cell production 39 . It has also been shown that undifferentiated HSPCs produce a wide range of cytokines upon stimulation and these cells are significantly more potent cytokine secretors than are mature immune cells 40 . It will be of interest to further investigate whether CD34 + cells from individuals with FSGS produce distinct cytokines that are capable of stimulating the mouse hematopoietic system to become pathogenic, leading to an increase of suPAR and induce proteinuria.
In conclusion, this study further demonstrates a direct pathogenic role of suPAR as a circulating mediator of kidney disease, such as FSGS. Given its specific cellular source, suPAR-associated renal diseases may originate as a primary hematopoietic stem cell disorder, providing novel functions for BM in extrarenal regulation of the glomerular filtration barrier. In addition, our findings serve as a prototype for the pathogenesis of other diseases in which BM progenitors may regulate organ function via soluble mediators presently categorized as 'idiopathic' . Stem cell transplantation may prove to be a viable approach to treat diseases such as suPAR-associated kidney disease.
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